Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Erika Hamilton, MD

The ELECTRA trial is seeking to evaluate the combination of elacestrant with abemaciclib in patients with ER+/HER2- metastatic breast cancer regardless of metastatic site and ESR1 status to see if this could be an all-oral treatment option before using fulvestrant-based combinations or chemotherapy-based regimens. And now, the preliminary results are here. Joining Dr. Charles Turck to share what we’ve learned so far from the ELECTRA trial is study investigator Dr. Erika Hamilton.

Host: Lee P. Shulman, MD, FACMG, FACOG

Guest: Linda Bradley, MD

Guest: Melissa Simon, MD

Both provider- and patient-related healthcare disparities exist in the diagnosis and management of endometriosis. Many disparities derive from incorrect historical biases, while others are associated with social determinants of health, or SDOH. Join Drs. Lee Shulman, Linda Bradley, and Melissa Simon as they address these issues to help facilitate a patient-centered practice environment for all patients.

Host: Lee P. Shulman, MD, FACMG, FACOG

Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP

Guest: Sawsan As-Sanie, MD

GnRH antagonists have emerged as a viable first-line (or subsequent-line) medical therapy for the management of endometriosis. They have proven to be effective and safe, and their use avoids the flare response observed with GnRH agonists. Join Drs. Lee Shulman, Ayman Al-Hendy, and Sawsan As-Sanie as they discuss the estrogen threshold hypothesis from the perspective of GnRH antagonists and delve into clinical data supporting the use of GnRH antagonists in the medical management of endometriosis.

Host: Lee P. Shulman, MD, FACMG, FACOG

Guest: Linda Bradley, MD

Guest: Melissa Simon, MD

The use of validated patient questionnaires, notably the SF-36 and EHP-30 scales, can greatly hasten the suspicion for an endometriosis diagnosis. Coupled with shared decision-making, or SDM, this patient-centered process can help ensure therapeutic adherence. Join Drs. Lee Shulman, Melissa Simon, and Linda Bradley as they discuss how to utilize the SF-36 and EHP-30 questionnaires in clinical practice and explore strategies to facilitate patient-healthcare provider discussions to improve overall short- and long-term patient outcomes.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA

Guest: Leigh Anne Cantrell, MD, MSPH

The updated ASCCP guidelines now address the use of dual-stain technology for cervical cancer management. CINtec PLUS Cytology is a test for the co-expression of p16 and Ki67 and confirms the presence of a transforming HPV infection and defines patients with high-risk cervical disease. To learn more about these guidelines and how to apply them in practice, join Dr. Leigh Cantrell, Medical Physician and Fellow in the American College of Obstetrics and Gynecology.

COBAS and CINTEC are trademarks of Roche.
All other product names and trademarks are the property of their respective owners. 07/24

Host: Ashley Baker, MSN, PMHNP

Guest: Kathleen Nadeau, PhD

Girls and women with ADHD are often underdiagnosed and undertreated compared to boys and men, which puts them at risk of serious issues like unplanned pregnancies, cigarette smoking, and even anxiety and depression. To help us better identify and manage girls and women with ADHD, psychiatric nurse practitioner Ashley Baker speaks with Dr. Kathleen Nadeau, Founder and Clinical Director of the Chesapeake Center for ADHD Learning and Behavioral Health in Bethesda, Maryland.

Guest: Kathleen Nadeau, PhD

It’s important to be aware of the different ways ADHD impacts girls and women compared to boys and men, which is why Dr. Kathleen Nadeau is here to help shed light on those differences. Dr. Nadeau is the Founder and Clinical Director of the Chesapeake Center for ADHD Learning and Behavioral Health in Bethesda, Maryland.

Host: Jennifer Caudle, DO

Guest: Tamera A. Paczos, MD, FACOG, FACP

The utility of p16 and Ki-67 immunostaining in biopsies has helped lead to the development of dual staining in cytology specimens. So what do clinicians need to know about the dual stain cytology test? Take a deep dive into this topic as Dr. Jennifer Caudle is joined by Dr. Tamera A. Paczos, Vice President, Associate Chief Medical Officer with BioReference Laboratories.

COBAS and CINTEC are trademarks of Roche.
All other product names and trademarks are the property of their respective owners. 02/23

Host: Warner K. Huh, MD

Guest: Kimberly Levinson, MD, MPH

More effective triage tests are essential to improving cervical cancer risk-stratification and thus reducing the potential for unnecessary colposcopies. Enduring consensus cervical cancer screening recommendations, published in 2024, describe specific-use algorithms for p16/Ki-67 dual-staining cytology as an effective triage test, and also offer insight on how this test can best fit into clinical practice. Join Drs. Warner Huh and Kimberly Levinson as they first establish the rationale for using p16/Ki-67 dual-staining cytology and then break down the most salient algorithms for its use as offered in the recent recommendations.

Host: Michael Lewiecki, MD, FACP, FACE

Although step therapy is the approach that many health plans and organizations are fond of, individualizing treatment decisions for patients with osteoporosis is essential, especially those who are at risk of fractures. To learn how you can create personalized treatment plans for patients with osteoporosis, tune in to hear Dr. Michael Lewiecki give us a recap of the session he presented at the 2024 Congress of Clinical Rheumatology.